Drug profile · INN
aclidinium bromide
BRETARIS GENUAIR
aclidinium bromide (BRETARIS GENUAIR) is a muscarinic acetylcholine receptor m3 antagonist. Route of administration: inhalation. Current US regulatory status: approved.
Drug details — aclidinium bromide
- US status
- approved
- Class
- Respiratory system (R03)
- Route
- INHALATION
- Patents
- 2
- Programs
- 2
- Data quality
- 0.84
Quick answer
aclidinium bromide (BRETARIS GENUAIR) is a muscarinic acetylcholine receptor m3 antagonist. Route of administration: inhalation. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M3 antagonist
Primary target: Muscarinic acetylcholine receptor M3
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is aclidinium bromide?
aclidinium bromide (BRETARIS GENUAIR) is a muscarinic acetylcholine receptor m3 antagonist. Route of administration: inhalation. Current US regulatory status: approved.
What is the brand name for aclidinium bromide?
BRETARIS GENUAIR is a marketed brand name for aclidinium bromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of aclidinium bromide?
aclidinium bromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.